Scale-Up Of An Adherent rAAV Production Process From The iCELLis™ Nano To iCELLis 50 And iCELLis 500+ Bioreactors

By Anne MacIntyre, Sara Krekels, Andrew Laskowski, Kelly Cybulski, and Michelle Olson Peabody, Cytiva

As gene therapy continues to advance, the need for scalable and efficient viral vector manufacturing grows. Adherent cell culture systems remain a key platform for producing viral vectors, but scaling these processes can be complex. Fixed-bed bioreactors offer a promising solution, enabling high-yield production in a controlled environment. The iCELLis™ bioreactor family now includes the iCELLis 50, designed to bridge the gap between small-scale development and large-scale manufacturing. With capacities ranging from 6 to 50 m², it provides a flexible intermediate option. Comparative studies across the Nano, 50, and 500+ formats show consistent metabolic profiles and rAAV5 titers, confirming the platform’s scalability. For teams navigating the transition from process development to commercial production, the iCELLis 50 offers a practical and validated path forward.

Explore the full poster to see how this system supports scalable gene therapy manufacturing.